CALHM2 V136G polymorphism reduces astrocytic ATP release and is associated with depressive symptoms and Alzheimer's disease risk
Alzheimer's & Dementia · 2023
DOI: 10.1002/alz.13366 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alzheimer's & Dementia, 2023. Verfasst von Yang Liao und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Brain Science Center, Beijing Institute of Basic Medical Sciences, Beijing, China. Hauptthemen laut MEDLINE: Alzheimer Disease, Astrocytes, Depression, Polymorphism, Single Nucleotide. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 50 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Major Project of Support Program, Young Elite Scientist Sponsorship Program by CAST.
Themen: Depression, Demenz
Abstract (Originalsprache)
INTRODUCTION Depression is considered a prodromal state of Alzheimer's disease (AD), yet the underlying mechanism(s) by which depression increases the risk of AD are not known. METHODS Single‐nucleotide polymorphism (SNP) analysis was used to determine the CALHM2 variants in AD patients. Cellular and molecular experiments were conducted to investigate the function of CALHM2 V136G mutation. We generated a new genetically engineered Calhm2 V136G mouse model and performed behavioral tests with these mice. RESULTS CALHM2 V136G mutation (rs232660) is significantly associated with AD. V136G mutation resulted in loss of the CALHM2 ATP‐release function in astrocytes and impaired synaptic plasticity. Mice homozygous for the Calhm2 V136G allele displayed depressive‐like behaviors that were rescued by administration of exogenous ATP. Moreover, Calhm2 V136G mutation predisposed mice to cognitive decline in old age. DISCUSSION CALHM2 dysfunction is a biologically relevant mechanism that may contribute to the observed clinical correlation between depression and AD.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The Brain Science Center, Beijing Institute of Basic Medical Sciences, Beijing, China.
- Department of Neurology in Second Affiliated Hospital, and Key Laboratory of Medical Neurobiology of Zhejiang Province, Zhejiang University School of Medicine, Hangzhou, China.
- Center on Translational Neuroscience, College of Life and Environmental Sciences, Minzu University of China, Beijing, China.
- Key Laboratory of Mental Health of the Ministry of Education, Guangdong-Hong Kong-Macao Greater Bay Area Center for Brain Science and Brain-Inspired Intelligence, Guangdong Province Key Laboratory of Psychiatric Disorde…
ORCID-Profile: Rui-Yuan Pan, Zengqiang Yuan
Förderung
- National Natural Science Foundation of China
- National Major Project of Support Program
- Young Elite Scientist Sponsorship Program by CAST
- China Postdoctoral Science Foundation
Zitieren
APA
Liao, Y., Wang, Y., Tao, Q. Q., Yang, C., Wang, J., Cheng, J., Ma, J., Wu, Z. Y., Pan, R. Y., & Yuan, Z. (2023). CALHM2 V136G polymorphism reduces astrocytic ATP release and is associated with depressive symptoms and Alzheimer's disease risk. Alzheimer's & Dementia. https://doi.org/10.1002/alz.13366
Vancouver
Liao Y, Wang Y, Tao QQ, Yang C, Wang J, Cheng J, et al. CALHM2 V136G polymorphism reduces astrocytic ATP release and is associated with depressive symptoms and Alzheimer's disease risk. Alzheimer's & Dementia. 2023. doi:10.1002/alz.13366
BibTeX
@article{Liao2023,
author = {Liao, Yang and Wang, Yingyi and Tao, Qing-Qing and Yang, Chaoguang and Wang, Jinlei and Cheng, Jinbo and Ma, Jun and Wu, Zhi-Ying and Pan, Rui-Yuan and Yuan, Zengqiang},
title = {CALHM2 V136G polymorphism reduces astrocytic ATP release and is associated with depressive symptoms and Alzheimer's disease risk},
journal = {Alzheimer's & Dementia},
year = {2023},
doi = {10.1002/alz.13366}
}
EUVIMED